Company Profile
BeyondSpring, Inc. Stock Price, News & Analysis
- Ticker:
- BYSI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.87 USD (-10.84%)
Close
Last updated: August 6, 2026
69.9M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, BYSI closed down 10.8% at $0.8700. No new same-company headline was identified in the current news window.
Company overview
Oncology Therapeutics Company
BeyondSpring develops first-in-class cancer therapies and supports a separately operated molecular glue degrader discovery platform through SEED Therapeutics.
Plinabulin
Plinabulin is a late-stage asset studied across multiple cancers and is being positioned as a combination backbone that may improve both efficacy and tolerability of antibody-drug conjugate regimens.
Combination Strategy
Preclinical work combines plinabulin with topoisomerase inhibitor ADCs and immune checkpoint inhibitors to address resistance and treatment-limiting toxicity.
SEED Platform Exposure
SEED Therapeutics applies structure-based discovery to molecular glue degraders, giving BeyondSpring economic exposure to a separate targeted protein degradation pipeline.
Future catalysts
BeyondSpring’s catalysts are plinabulin and the company’s oncology / supportive-care programs, where the next update can either keep the story alive or push it further into the background. The stock is still sensitive to whether the clinical path stays credible.
Recent news
- 01
- 02
- 03
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
Source: BeyondSpring, Inc.
- 04
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
Source: BeyondSpring, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BeyondSpring, Inc. (BYSI)?
BeyondSpring, Inc. (BYSI) most recently closed at 0.87 USD, a -10.84% move versus the previous session.
What is the market cap of BeyondSpring, Inc. (BYSI)?
BeyondSpring, Inc. currently has a market capitalization of 69.9M USD on BioPharmSignal.
What does BeyondSpring, Inc. do?
Oncology Therapeutics Company BeyondSpring develops first-in-class cancer therapies and supports a separately operated molecular glue degrader discovery platform through SEED Therapeutics. Plinabulin Plinabulin is a late-stage asset studied across multiple cancers and is being positioned as a combination backbone that may improve both efficacy and...
On which exchange is BYSI stock listed?
BeyondSpring, Inc. (BYSI) is associated with NASDAQ, United States, Biopharma.
What is Oncology?
BeyondSpring’s catalysts are plinabulin and the company’s oncology / supportive-care programs, where the next update can either keep the story alive or push it further into the background.
Which conditions is BeyondSpring, Inc. targeting with Oncology?
BeyondSpring, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does BeyondSpring, Inc. describe recent progress with Oncology?
BeyondSpring’s catalysts are plinabulin and the company’s oncology / supportive-care programs, where the next update can either keep the story alive or push it further into the background.
What is Therapeutics?
Oncology Therapeutics Company BeyondSpring develops first-in-class cancer therapies and supports a separately operated molecular glue degrader discovery platform through SEED Therapeutics.